← All trials
NCT04894617
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2021
- Primary completion
- Jan 31, 2022
- Completion date
- Apr 30, 2022
- First posted
- May 20, 2021
- Last posted
- Oct 6, 2021
- Enrollment
- 226
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenReponsible party - principal investigator
- University of CopenhagenOverall official - principal investigator
- University of CopenhagenCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.